244194-67-0

Basic information

• Product Name: 2-(3-chloro-4-fluorophenyl)ethanamine
• Synonyms: 2-(3-chloro-4-fluorophenyl)ethanamine;2-(3-Chloro-4-fluorophenyl)ethylamine
• CAS NO: 244194-67-0
• Molecular Formula: C₈H₉ClFN
• Molecular Weight: 173.6151632
• Mol File: 244194-67-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3-chloro-4-fluorophenyl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-chloro-4-fluorophenyl)ethanamine(244194-67-0)
• EPA Substance Registry System: 2-(3-chloro-4-fluorophenyl)ethanamine(244194-67-0)

Safety Data

• Hazardous Substances Data: 244194-67-0(Hazardous Substances Data)

Usage

General Description

2-(3-chloro-4-fluorophenyl)ethanamine is a chemical compound with the molecular formula C8H8ClFN. It is a derivative of phenylethylamine, containing a chloro and fluoro substituent on the phenyl ring. 2-(3-chloro-4-fluorophenyl)ethanamine is primarily used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It has been found to exhibit some potential biological activities, including as a serotonin receptor agonist, making it of interest in the development of new medications for mood disorders and related conditions. However, it is important to handle this compound with care, as it may pose hazards to human health and the environment if not used properly.

Upstream product

• 658-98-0 2-(3-chloro-4-fluorophenyl)acetonitrile 
• 161446-90-8 3-chloro-4-fluorobenzyl alcohol 
• 192702-01-5 3-chloro-4-fluorobenzyl bromide 

Downstream Products

• 875305-53-6 2-(3-chloro-4-fluoro-phenyl)-ethylamine hydrochloride 
• 1060788-13-7 (S)-1-(4-methanesulfonamidophenoxy)-3-(3-chloro-4-fluorophenylethylamino)-2-propanol 
• 1440519-55-0 N-[2-(3-chloro-4-fluoro-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 
• 1365760-92-4 [2-(3-chloro-4-fluoro-phenyl)-ethyl]-carbamic acid ethyl ester 

Relevant articles and documents

Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors

Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone levels, which are associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS). A benzamide pyridine hit derived from a focused screen was successfully developed into a series of potent and selective 3-pyridyl isoindolin-1-ones CYP11B2 inhibitors. Our systematic structure-activity relationship study enabled us to identify unique structural features that result in high selectivity against the closely homologous cortisol synthase (CYP11B1). We evaluated advanced lead molecules, exemplified by compound 52, in an in vivo cynomolgus monkey acute adrenocorticotropic hormone (ACTH) challenge model and demonstrated a superior 100-fold in vivo selectivity against CYP11B1.

NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, A1, A2, A3, A4, A5 and n are as described herein,compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrom.

Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists

Enantiomeric propanolamines have been identified as a new class of NR2B-selective NMDA receptor antagonists. The most effective agents are biaryl structures, synthesized in six steps with overall yields ranging from 11-64%. The compounds are potent and selective inhibitors of NR2B-containing recombinant NMDA receptors with IC50 values between 30-100 nM. Potency is strongly controlled by substitution on both rings and the centrally located amine nitrogen. SAR analysis suggests that well-balanced polarity and chain-length factors provide the greatest inhibitory potency. Structural comparisons based on 3D shape analysis and electrostatic complementarity support this conclusion. The antagonists are neuroprotective in both in vitro and in vivo models of ischemic cell death. In addition, some compounds exhibit anticonvulsant properties. Unlike earlier generation NMDA receptor antagonists and some NR2B-selective antagonists, the present series of propanolamines does not cause increased locomotion in rodents. Thus, the NR2B-selective antagonists exhibit a range of therapeutically interesting properties.